AZD5363
| CAS No. | 1143532-39-1 | Cat. No. | BCP04083 |
| Name | AZD5363 | ||
| Synonyms | AZD-5363; AZD 5363; Capivasertib; | ||
| Formula | C21H25ClN6O2 | M. Wt | 428.92 |
| Description | AZD5363, a novel pyrrolopyrimidine-derived compound, inhibited all AKT isoforms.AZD5363 has potential to treat a range of solid and hematologic tumors as monotherapy or a combinatorial agent, and has potential for personalized medicine based on the genetic status of PIK3CA, PTEN, and RAS. in vitro: AZD5363, a novel pyrrolopyrimidine-derived compound, inhibited all AKT isoforms with a potency of 10 nmol/L or less and inhibited phosphorylation of AKT substrates in cells with a potency of approximately 0.3 to 0.8 μmol/L. AZD5363 monotherapy inhibited the proliferation of 41 of 182 solid and hematologic tumor cell lines with a potency of 3 μmol/L or less. | ||
| Pathways | PI3K/Akt/mTOR | ||
| Targets | AKT | ||
Structure
Part data of this page collected from the open network resources, so Biochempartner can not guarantee its accuracy.
For product details of different batches, please contact our Customer
- Service & Tech Support:orders@biochempartner.com
- Website:www.biochempartner.com
Products are for research use only and not for human use. We do not sell to patients.